Expression of human endogenous retrovirus type W (HERV-W) has been linked to
cancer, making HERV-W
antigens potential targets for therapeutic
cancer vaccines. In a previous study, we effectively treated established tumours in mice by using adenoviral-vectored
vaccines targeting the murine endogenous retrovirus envelope and group-specific
antigen (Gag) of
melanoma-associated retrovirus (MelARV) in combination with anti-PD-1. To break the immunological tolerance to MelARV, we mutated the immunosuppressive domain (ISD) of the MelARV envelope. However, reports on the immunogenicity of the HERV-W envelope,
Syncytin-1, and its ISD are conflicting. To identify the most effective HERV-W
cancer vaccine candidate, we evaluated the immunogenicity of
vaccines encoding either the wild-type or mutated HERV-W envelope ISD in vitro and in vivo. Here, we show that the wild-type HERV-W
vaccine generated higher activation of murine antigen-presenting cells and higher specific T-cell responses than the ISD-mutated counterpart. We also found that the wild-type HERV-W
vaccine was sufficient to increase the probability of survival in mice subjected to HERV-W envelope-expressing tumours compared to a control
vaccine. These findings provide the foundation for developing a therapeutic
cancer vaccine targeting HERV-W-positive
cancers in humans.